List of Tivorbex drug patents

Tivorbex is owned by Genus.

Tivorbex contains Indomethacin.

Tivorbex has a total of 3 drug patents out of which 0 drug patents have expired.

Tivorbex was authorised for market use on 24 February, 2014.

Tivorbex is available in capsule;oral dosage forms.

Tivorbex can be used as treatment of pain.

The generics of Tivorbex are possible to be released after 23 April, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734847 GENUS Formulation of indomethacin
Apr, 2030

(7 years from now)

US9089471 GENUS Formulation of indomethacin
Apr, 2030

(7 years from now)

US8992982 GENUS Formulation of indomethacin
Apr, 2030

(7 years from now)

Drugs and Companies using INDOMETHACIN ingredient

Market Authorisation Date: 24 February, 2014

Treatment: Treatment of pain

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in